SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is trending amid intense community debate, largely driven by ongoing price depreciation attributed to tax loss harvesting and persistent selling pressure from SPAC-related share overhang. Despite recent inclusion in the Russell 2000/3000 indexes and reported strong revenue growth in its latest quarter, sentiment remains highly polarized. Bulls view the stock as deeply undervalued with significant long-term potential from user growth and international expansion, while bears warn of continued dilution and question the company's valuation.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for NEREUS (tradipitant), hailed as the first new motion sickness drug in over 40 years. The community is buzzing about its substantial potential to address GLP-1 induced nausea and vomiting, viewing this as a significant market expansion that could drive a revaluation of the company. With additional pipeline catalysts anticipated, many are expressing strong conviction in its future growth, despite some predicting immediate profit-taking.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is actively debated amid its significant price volatility, with many investors anticipating potential breakthroughs and new partnerships at the upcoming CES 2026. While some highlight its robust contractual backlog, growing revenues in voice AI, and debt-free status as a compelling buying opportunity, others express deep skepticism regarding management's communication and the stock's recent performance.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid sharp investor division, primarily driven by the recent FDA approval of Novo Nordisk's oral Wegovy pill and speculation around potential distribution partnerships for GLP-1 treatments. While many note the stock's significant drawdown and high short interest as bearish indicators, others view the current valuation as a prime long-term buying opportunity, citing strong fundamentals, institutional accumulation, and the company's expansion into new health verticals and international markets. The community is actively debating whether the current dip sets the stage for a short squeeze or further decline for the direct-to-consumer telehealth provider.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is currently trending amidst significant investor frustration as its stock repeatedly hits new all-time lows, fueling widespread community debate over perceived management effectiveness and production execution. Despite recent accolades for its Gravity SUV and strategic partnerships, conversation is heavily focused on the extended interim CEO tenure, potential dilution, and critical concerns about meeting annual vehicle production targets compared to surging EV competitors.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token ($YEE) is trending with strong community conviction as it achieves new all-time highs and sees increased market activity, fueled by its growing presence on Ethereum. The community is actively discussing its sustained momentum, robust chart action, and a narrative positioning it as a significant player in the ongoing "ETH season" amidst broader market shifts.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is actively trending following news of a proposed business combination with Applied Digital, aiming to spin out APLD's cloud division into ChronoScale, an AI compute platform. This potential pivot into AI infrastructure, combined with EKSO's low float, has ignited fierce debate among traders about significant upside, while others emphasize substantial dilution for existing shareholders. The community is focused on the immediate trading opportunities and high volume, comparing it to other volatile low-float plays.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid choppy, low-volume trading as market participants grapple with mixed signals from recent Fed minutes regarding future rate policy. Community discussions are sharply divided, with bulls anticipating continued strength towards new highs and bears predicting an imminent correction, particularly as the anticipated "Santa Rally" appears to be largely absent.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

Gasspas ($GASS) is currently a hot topic among crypto communities, with many drawing parallels to early Pepe and some associating it with creator Matt Furie. Enthusiasts are actively accumulating due to its low market capitalization, anticipating significant price movements and aiming to 'drop a zero' in its value as part of a broader meme coin rally.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is a major talking point as its repeatedly delayed proxy vote on increasing authorized shares fuels investor anxiety, with many debating if it signals essential growth capital or future dilution. The community is buzzing with speculation about impending government AI and defense contracts, including potential classified work and the integration of strategic acquisitions like Ask Sage. This creates a highly polarized environment, where optimism for the company's long-term defense sector role clashes with concerns over near-term execution and market uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dermata Therapeutics Announces A Private Placement Valued At Up To $12.4 Mln

(RTTNews) - Dermata Therapeutics Inc. (DRMA), a dermatologic firm, announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2.02 million shares of common...

Why Is Dermata Therapeutics Stock Surging Wednesday?

Dermata Therapeutics rose after announcing a private placement offering of common shares, Series C warrants, and Series D warrants.read more...

<ul class="summary-bullets"><li>The offering, alongside two series of warrants that permit future purchases of the same amount of shares, is priced at $2.04 per unit.&nbsp;</li><li>The company plans to use the proceeds for general corporate needs, including consumer research and rollout activities for its forthcoming over‑the‑counter acne kit.</li><li>In early December, Dermata said it is preparing to launch a fresh brand identity for its over-the-counter skincare line.</li></ul>Dermata Therapeutics, Inc. (DRMA) stock surged 22% in Wednesday’s premarket after the company announced that it has struck definitive agreements to issue roughly 2.02 million shares of its common stock in a private placement deal.&nbsp;The offering, alongside two series of warrants that permit future purchases of the same amount of shares, is priced at $2.04 per unit.&nbsp;<h2 class="st-heading-2">Use Of Proceeds</h2>Dermata expects roughly $4.1 million in gross proceeds initially, before fees and expenses. If all new warrants are exercised for cash, the number could rise by approximately $8.3 million, bringing total potential funding to nearly $12.4 million.&nbsp;The company plans to use the proceeds for general corporate needs, including consumer research, rollout activities for its forthcoming over‑the‑counter acne kit, licensing initiatives, possible strategic investments, and working capital.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/DRMA">Dermata Therapeutics’ stock</a> traded over 24% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. At the same time, message volume shifted to ‘extremely high’ from ‘extremely low’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:934/106;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_084540_png_7928eb6a71.webp" alt="DRMA’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Dec. 24, 2025 | Source: Stocktwits" width="934" height="106"><figcaption>DRMA’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Dec. 24, 2025 | Source: Stocktwits</figcaption></figure>Dermata creates science-based skin treatments with a focus on over-the-counter (OTC) skin products.&nbsp;<h2 class="st-heading-2">Dermata’s&nbsp;Skincare Line</h2>In early December, the company said it is preparing to launch a fresh brand identity for its over-the-counter skincare line, signaling a move toward a science-driven, direct-to-consumer model.&nbsp;Central to the rebrand is Dermata’s proprietary Spongilla technology, which is expected to enhance the efficacy of routine skincare. By simplifying regimens and boosting results, the products are designed to amplify the overall effectiveness of a skincare routine.The latest funding strategy with a fresh financing move is aimed at extending the runway for the company’s upcoming consumer skin‑care initiatives.&nbsp;DRMA stock has declined 84% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intel-s-manufacturing-push-faces-fresh-test-after-nvidia-passes-on-18-a-chips-report/cLesu73REv4">Intel’s Manufacturing Push Faces Fresh Test After Nvidia Passes On 18A Chips: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Dermata Therapeutics Stock Surge 22% Pre-Market Today?

The company has entered into definitive agreements to issue roughly 2.02 million shares of its common stock in a private placement deal. 

Equity

The company has entered into definitive agreements to issue roughly 2.02 million shares of its common stock in a private placement deal. 


Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.

DRMA
Dermata Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DRMA News

DRMADermata Therapeutics Inc